Tymlos - (3.12 mg/1.56 mL (2mg/mL); Subcutaneous Injection)

Generic Name	Abaloparatide	Innovator	Radius Health
Dosage	3.12 mg/1.56 mL (2mg/mL); Subcutaneous Injection	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	TYMLOS is a human parathyroid hormone related peptide [PTHrP(1-34)] analog indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*********	*** \ *********	*** **, ****	********* ******* / **** ** ** / ******** ** **	****	******* *** **** *** *** ****

Chronology Of Events